首页|期刊导航|Hepatobiliary & Pancreatic Diseases International|Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1(IDH1)-mutant cholangiocarcinoma:An Italian perspective

Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1(IDH1)-mutant cholangiocarcinoma:An Italian perspectiveOA

中文摘要

Recently,Abou-Alfa et al.[1]have presented the results of the ClarIDHy trial,a phase III randomized controlled trial(RCT)that have compared ivosidenib,a small-molecule targeted inhibitor of mutated isocitrate dehydrogenase 1(IDH1)versus placebo in pa-tients with previously treated IDH1-mutant cholangiocarcinoma.The primary endpoint was progression free survival(PFS).Median PFS with ivosidenib was significantly improved compared with placebo[2.7 months vs.1.4 months,hazard ratio(HR)=0.37,95%confidence interval(CI):0.25–0.54,P<0.0001].Median overall sur-vival(OS)was 10.3 months with ivosidenib versus 7.5 months with placebo(HR=0.79,95%CI:0.56–1.12,P=0.09).When adjusted for crossover,median OS with placebo was 5.1 months(HR=0.49,95%CI=0.34–0.70,P<0.001)[2].Serious adverse events were reported in 9.0%in the ivosidenib group and 7.0%in the placebo group.

Jacopo Giuliani;Emilia Durante;Marco Muraro;Silvia Muraro;Marina Tommasi;Francesco Fiorica;Teodoro Sava

Department of Oncology,Azienda ULSS 9 Scaligera,Legnago,ItalyDepartment of Oncology,Azienda ULSS 9 Scaligera,Legnago,ItalyDepartment of Oncology,Azienda ULSS 9 Scaligera,Legnago,ItalyPharmaceutical Department,Azienda ULSS 9 Scaligera,Legnago,ItalyPharmaceutical Department,Azienda ULSS 9 Scaligera,Legnago,ItalyDepartment of Oncology,Azienda ULSS 9 Scaligera,Legnago,ItalyDepartment of Oncology,Azienda ULSS 9 Scaligera,Legnago,Italy

医药卫生

progression free survival pfs medianProgression Free SurvivalClaridhy Trialclaridhy trialaIvosidenibisocitrate dehydrogenase idh versusphase iii randomized controlled trial rctCholangiocarcinoma

《Hepatobiliary & Pancreatic Diseases International》 2026 (4)

P.446-448,3

10.1016/j.hbpd.2025.12.018

评论